Roivant Says Immunovant Reported Results From Phase 2a Trial Of Batoclimab In Graves' Disease; Says High Dose Batoclimab Achieved 76% Response Rate In Patients Uncontrolled On Antithyroid Drugs At Week 12

Author: Benzinga Newsdesk | September 09, 2024 07:06am

mmunovant also disclosed data from several proprietary market research studies that showed a consistent unmet need among ATD treated patients who are intolerant to, uncontrolled on or relapsed after ATDs.

Finally, Immunovant also announced alignment with the FDA and Investigational New Drug Application clearance with initiation of a pivotal trial of IMVT-1402 in GD expected by December 31, 2024.

• High dose batoclimab achieved 56% ATD-free response rate in patients uncontrolled on ATDs at week 12
• Strong correlation observed between degree of IgG lowering and clinical outcomes yields potential best-in-class and first-in-class opportunity for IMVT-1402 in Graves' Disease (GD)
• IND cleared with initiation of IMVT-1402 pivotal trial in GD expected by calendar year end

Posted In: IMVT ROIV